Brief: Guard Therapeutics Gets Conditional Approval For Continued Listing
17/07/2026 06:28
BRIEF-Guard Therapeutics Gets Conditional Approval For Continued Listing July 17 (Reuters) - Guard Therapeutics International AB GUARD.ST:
SAID ON THURSDAY IT HAS RECEIVED CONDITIONAL APPROVAL FROM NASDAQ STOCKHOLM TO KEEP ITS NASDAQ FIRST NORTH LISTING TIED TO ITS PLANNED ACQUISITION OF DISRUPTIVE PHARMA
Source text for Workspace: nMFN80zrTR
Further company coverage: GUARD.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Disruptive Pharma AB (publ)
See all newsBrief: Disruptive Pharma To Sell GTX Platform To Aurelia Invest AB Unit
Brief: Guard Therapeutics International Q2 Loss Before Tax SEK 4.4 Mln
Brief: Guard Therapeutics Gets Conditional Approval For Continued Listing
Brief: Guard Therapeutics International Initiates Deal Process For Gtx Platform
Brief: Guard Therapeutics Enters Conditional Deal For Reverse Takeover